胸部放疗联合免疫治疗时代肺炎发生的影响因素  

Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy

作　　者：黄华玉 龚虹云[1] 宋启斌[1] Huang Huayu;Gong Hongyun;Song Qibin(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《国际肿瘤学杂志》2023年第2期102-106,共5页Journal of International Oncology

摘　　要：胸部放疗联合免疫治疗在临床应用越来越广泛,在带来生存获益的同时也增加了肺炎发生率。肺炎的发生不仅影响后续免疫治疗,严重者可危及生命。联合治疗后肺炎的发生及其严重程度取决于多种因素,包括患者年龄、体力、肺功能、种族、联合治疗模式、放疗剂量参数、免疫抑制剂种类、既往免疫相关性肺炎或放射性肺炎病史、血清学指标等。目前仍需进一步研究,找出联合治疗后肺炎发生及严重程度的影响因素,以期在临床实践中更好地规避、预测、识别和治疗相关肺炎。The combination of thoracic radiotherapy and immunotherapy is increasingly widely used in clinical practice,which not only brings survival benefits but also increases the incidence of pneumonitis.The occurrence of pneumonitis affects the subsequent immunotherapy and can be life-threatening in severe cases.The occurrence and severity of pneumonitis after combination therapy depends on a variety of factors,including patient's age,physical strength,pulmonary function,race,combination therapy mode,radiotherapy dose parameters,type of immune checkpoint inhibitor,history of checkpoint inhibitor-related pneumonitis or radiation pneumonitis,serum indexes and so on.At present,further research is needed to find out the influencing factors of the occurrence and severity of pneumonitis attributed to combined therapy,so as to better avoid,predict,identify and treat related pneumonitis in clinical practice.

关 键 词：胸部放疗 免疫治疗 肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]